Mexiletine therapy in 15 patients with drug-resistant ventricular tachycardia

James J. Heger, Stanley Nattel, Robert L. Rinkenberger, Douglas P. Zipes

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Mexiletine therapy was administered to 15 patients with chronic and recurrent episodes of ventricular tachycardia or ventricular fibrillation. All patients were intolerant of or had arrhythmias resistant to conventional antiarrhythmic agents. At maximal dosages of mexiletine 2 patients had more than 90 percent reduction in frequency of premature ventricular complexes, whereas 11 patients had less than 50 percent reduction, as measured on 24 hour electrocardiographic recordings. Mexiletine was unsuccessful in preventing or abolishing ventricular tachycardia in 11 patients. Adverse side effects occurred in nine patients (60 percent) and were severe enough to necessitate discontinuation of therapy in six patients (40 percent). Side effects appeared to be dosage-related. Pharmacokinetic analysis indicated a mean elimination half-life of 12.6 ± 1.6 hours following oral administration of mexiletine. In the patients studied, mexiletine exhibited limited antiarrhythmic efficacy and was associated with frequent adverse side effects.

Original languageEnglish
Pages (from-to)627-632
Number of pages6
JournalThe American Journal of Cardiology
Volume45
Issue number3
DOIs
StatePublished - 1980

Fingerprint

Mexiletine
Ventricular Tachycardia
Pharmaceutical Preparations
Therapeutics
Ventricular Premature Complexes
Ventricular Fibrillation
Oral Administration
Half-Life
Cardiac Arrhythmias
Pharmacokinetics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Mexiletine therapy in 15 patients with drug-resistant ventricular tachycardia. / Heger, James J.; Nattel, Stanley; Rinkenberger, Robert L.; Zipes, Douglas P.

In: The American Journal of Cardiology, Vol. 45, No. 3, 1980, p. 627-632.

Research output: Contribution to journalArticle

Heger, James J. ; Nattel, Stanley ; Rinkenberger, Robert L. ; Zipes, Douglas P. / Mexiletine therapy in 15 patients with drug-resistant ventricular tachycardia. In: The American Journal of Cardiology. 1980 ; Vol. 45, No. 3. pp. 627-632.
@article{f3a622db123443cc89a184e72b573e3e,
title = "Mexiletine therapy in 15 patients with drug-resistant ventricular tachycardia",
abstract = "Mexiletine therapy was administered to 15 patients with chronic and recurrent episodes of ventricular tachycardia or ventricular fibrillation. All patients were intolerant of or had arrhythmias resistant to conventional antiarrhythmic agents. At maximal dosages of mexiletine 2 patients had more than 90 percent reduction in frequency of premature ventricular complexes, whereas 11 patients had less than 50 percent reduction, as measured on 24 hour electrocardiographic recordings. Mexiletine was unsuccessful in preventing or abolishing ventricular tachycardia in 11 patients. Adverse side effects occurred in nine patients (60 percent) and were severe enough to necessitate discontinuation of therapy in six patients (40 percent). Side effects appeared to be dosage-related. Pharmacokinetic analysis indicated a mean elimination half-life of 12.6 ± 1.6 hours following oral administration of mexiletine. In the patients studied, mexiletine exhibited limited antiarrhythmic efficacy and was associated with frequent adverse side effects.",
author = "Heger, {James J.} and Stanley Nattel and Rinkenberger, {Robert L.} and Zipes, {Douglas P.}",
year = "1980",
doi = "10.1016/S0002-9149(80)80015-4",
language = "English",
volume = "45",
pages = "627--632",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Mexiletine therapy in 15 patients with drug-resistant ventricular tachycardia

AU - Heger, James J.

AU - Nattel, Stanley

AU - Rinkenberger, Robert L.

AU - Zipes, Douglas P.

PY - 1980

Y1 - 1980

N2 - Mexiletine therapy was administered to 15 patients with chronic and recurrent episodes of ventricular tachycardia or ventricular fibrillation. All patients were intolerant of or had arrhythmias resistant to conventional antiarrhythmic agents. At maximal dosages of mexiletine 2 patients had more than 90 percent reduction in frequency of premature ventricular complexes, whereas 11 patients had less than 50 percent reduction, as measured on 24 hour electrocardiographic recordings. Mexiletine was unsuccessful in preventing or abolishing ventricular tachycardia in 11 patients. Adverse side effects occurred in nine patients (60 percent) and were severe enough to necessitate discontinuation of therapy in six patients (40 percent). Side effects appeared to be dosage-related. Pharmacokinetic analysis indicated a mean elimination half-life of 12.6 ± 1.6 hours following oral administration of mexiletine. In the patients studied, mexiletine exhibited limited antiarrhythmic efficacy and was associated with frequent adverse side effects.

AB - Mexiletine therapy was administered to 15 patients with chronic and recurrent episodes of ventricular tachycardia or ventricular fibrillation. All patients were intolerant of or had arrhythmias resistant to conventional antiarrhythmic agents. At maximal dosages of mexiletine 2 patients had more than 90 percent reduction in frequency of premature ventricular complexes, whereas 11 patients had less than 50 percent reduction, as measured on 24 hour electrocardiographic recordings. Mexiletine was unsuccessful in preventing or abolishing ventricular tachycardia in 11 patients. Adverse side effects occurred in nine patients (60 percent) and were severe enough to necessitate discontinuation of therapy in six patients (40 percent). Side effects appeared to be dosage-related. Pharmacokinetic analysis indicated a mean elimination half-life of 12.6 ± 1.6 hours following oral administration of mexiletine. In the patients studied, mexiletine exhibited limited antiarrhythmic efficacy and was associated with frequent adverse side effects.

UR - http://www.scopus.com/inward/record.url?scp=0018832447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018832447&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(80)80015-4

DO - 10.1016/S0002-9149(80)80015-4

M3 - Article

VL - 45

SP - 627

EP - 632

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 3

ER -